Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17362870 | 0.86 | PDPK1 (0.40) | PDPK1MKNK2USP30ATRPOLB | |
| SCHEMBL30381577 | 0.86 | PDPK1 (0.40) | PDPK1MKNK2USP30ATRPOLB | |
| SCHEMBL17362697 | 0.84 | PDPK1 (0.39) | PDPK1MKNK2USP30ATRPOLB | |
| SCHEMBL17362914 | 0.82 | MKNK2 (0.41) | PDPK1MKNK2USP30ATRMT-CO2 | |
| SCHEMBL17362938 | 0.81 | PDPK1 (0.40) | PDPK1MKNK2USP30ATRSYK | |
| SCHEMBL17362762 | 0.81 | PDPK1 (0.40) | PDPK1MKNK2USP30ATRLMNA | |
| SCHEMBL18786676 | 0.80 | PDPK1 (0.39) | PDPK1MKNK2USP30SYKJAK3 | |
| SCHEMBL18786760 | 0.78 | PDPK1 (0.38) | PDPK1MKNK2USP30 | |
| SCHEMBL22582911 | 0.76 | ATR (0.40) | PDPK1USP30ATRSYKPOLB | |
| SCHEMBL28841945 | 0.76 | PDPK1 (0.37) | PDPK1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-110183449-B | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-11-04 | — | — | US | disclosed |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | Effector Therapeutics Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | Effector Therapeutics Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3697777-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | eFFECTOR Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3521289-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3521289-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | PDPK1 268/4885MKNK2 83/4885USP30 3921/4885 |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | PDPK1 268/4885MKNK2 83/4885USP30 3921/4885 |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | NEK5, MINK1, NIM1K | PDPK1 384/4885MKNK2 49/4885USP30 3634/4885 |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | PDPK1 268/4885MKNK2 83/4885USP30 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.